Impact of Metformin on Advanced Pancreatic Cancer Survival: Too Little, Too Late?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 26637275.
- Also identified by DOI 10.1158/1078-0432.CCR-15-2494 and PMC identifier 4775394.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Metformin offers no survival advantage in patients with metastatic pancreatic cancer. Despite promising experimental evidence suggesting an antitumor effect of metformin, its impact on the survival of advanced pancreatic cancer is likely very limited. Future studies may need to consider its role in early-stage pancreatic cancer. See related article by Reni et al., p. 1076.
Medical subject headings
- Metformin
- Pancreatic Neoplasms